B. Riley Wealth Advisors Inc. Reduces Holdings in DaVita Inc. (NYSE:DVA)

B. Riley Wealth Advisors Inc. decreased its holdings in DaVita Inc. (NYSE:DVA) by 9.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,101 shares of the company’s stock after selling 207 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in DaVita were worth $220,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in DVA. 8 Knots Management LLC purchased a new position in shares of DaVita in the fourth quarter worth approximately $89,504,000. Doma Perpetual Capital Management LLC bought a new stake in DaVita during the 4th quarter worth approximately $53,076,000. Norges Bank bought a new stake in DaVita during the 4th quarter worth approximately $36,626,000. Allianz Asset Management GmbH raised its stake in DaVita by 63.9% during the 4th quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock worth $57,476,000 after acquiring an additional 213,992 shares during the period. Finally, Pinebridge Investments L.P. raised its stake in DaVita by 148.8% during the 4th quarter. Pinebridge Investments L.P. now owns 268,601 shares of the company’s stock worth $28,139,000 after acquiring an additional 160,630 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Insider Buying and Selling

In related news, Director Barbara J. Desoer sold 5,030 shares of the business’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $138.81, for a total value of $698,214.30. Following the sale, the director now owns 10,954 shares in the company, valued at $1,520,524.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on DVA. StockNews.com cut shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Truist Financial raised their target price on shares of DaVita from $135.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, May 15th. Finally, Barclays raised their target price on shares of DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a research note on Monday, May 6th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $144.67.

DaVita Trading Down 0.5 %

DaVita stock opened at $141.45 on Friday. The stock has a market cap of $12.41 billion, a P/E ratio of 16.07, a PEG ratio of 1.09 and a beta of 0.96. The company has a debt-to-equity ratio of 7.95, a current ratio of 1.43 and a quick ratio of 1.37. DaVita Inc. has a 1 year low of $71.51 and a 1 year high of $147.93. The firm’s 50 day moving average price is $139.50 and its 200-day moving average price is $126.40.

DaVita (NYSE:DVA) last released its quarterly earnings data on Thursday, May 2nd. The company reported $2.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.43. The firm had revenue of $3.07 billion for the quarter, compared to analysts’ expectations of $3.03 billion. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.58 earnings per share. On average, equities analysts predict that DaVita Inc. will post 9.62 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.